Search - tctmd.com

Displaying 41 - 60 of 118

Sort: Relevancy | Date

News Daily News

Isolated SAVR Volumes Slide as TAVR Numbers Mount in the US

Yael L. Maxwell

October 19, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

News Industry News

Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

September 18, 2018

News Conference News The Structural Heart Disease Summit 2018

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Michael O'Riordan

June 22, 2018

News Conference News EuroPCR 2018

NOTION: TAVR in Low-Risk Patients Maintains Its Momentum Through 6 Years

Caitlin E. Cox

May 24, 2018

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

News Conference News CRT 2018

Transcatheter Fix for Native Aortic Valve Regurgitation ‘Not Optimal’ but Getting Better

Shelley Wood

March 05, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Daily News

Meta-analysis Raises ‘Red Flag’ on TAVR in Low-Risk Patients

L.A. McKeown

February 07, 2018

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

Todd Neale

November 09, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

News Daily News

Some Reassurances, Some Sobering Truths About Dialysis Needs After TAVR

Shelley Wood

October 16, 2017

News Conference News PCR London Valves 2017

Valve Deterioration and Durability Definitions Now Standardized in New Guide

Shelley Wood

September 25, 2017

News Conference News ESC 2017

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Michael O'Riordan

August 31, 2017

News Industry News

Keystone Heart Ltd to Accelerate Trials for Advanced Device to Protect Brain During Heart Procedures

August 01, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Daily News

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Michael O'Riordan

February 09, 2017

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Todd Neale

November 01, 2016

News Daily News

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Yael L. Maxwell

September 14, 2016

Advertisement

Isolated SAVR Volumes Slide as TAVR Numbers Mount in the US

High Mortality but Durable Results With Valve-in-Valve TAVR

Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

NOTION: TAVR in Low-Risk Patients Maintains Its Momentum Through 6 Years

Ticagrelor: Better Platelet Blockade Post-TAVR?

Transcatheter Fix for Native Aortic Valve Regurgitation ‘Not Optimal’ but Getting Better

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Meta-analysis Raises ‘Red Flag’ on TAVR in Low-Risk Patients

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Some Reassurances, Some Sobering Truths About Dialysis Needs After TAVR

Valve Deterioration and Durability Definitions Now Standardized in New Guide

Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days

Keystone Heart Ltd to Accelerate Trials for Advanced Device to Protect Brain During Heart Procedures

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content